Autor: |
Sae Ochi, Koshiro Sonomoto, Shingo Nakayamada, Yoshiya Tanaka |
Jazyk: |
angličtina |
Rok vydání: |
2024 |
Předmět: |
|
Zdroj: |
Arthritis Research & Therapy, Vol 26, Iss 1, Pp 1-11 (2024) |
Druh dokumentu: |
article |
ISSN: |
1478-6362 |
DOI: |
10.1186/s13075-024-03369-8 |
Popis: |
Abstract Background Rheumatoid arthritis (RA) patients sometimes exhibit different levels of improvement in health assessment questionnaire-disability index (HAQ-DI) and subjective pain visual analogue score (VAS) even after achieving low disease activities (LDA). This study aimed to identify factors associated with improvement in HAQ-DI and pain VAS among those who achieved LDA. Methods Data of the FIRST registry, a multi-institutional cohort of RA patients treated with biological and targeted-synthetic DMARDs (b/tsDMARDs) were analyzed. Patients who were enrolled from August 2013 to February 2023 and who achieved clinical LDA [clinical disease activity index (CDAI) ≤ 10.0] at 6 months after starting treatment were included. Multiple logistic regression analyses were conducted to identify the factors that associated with achieving HAQ-DI normalization ( 0.22), or pain VAS reduction (≤ 40 mm). Results Among 1424 patients who achieved LDA at 6 months, 732 patients achieved HAQ-DI normalization and 454 achieved pain VAS reduction. The seropositivity and the use of JAK inhibitor compared with TNF inhibitor were associated with both HAQ-DI |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|